key: cord-0855447-xm3eos7c
authors: Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad
title: Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19
date: 2022-03-17
journal: High Blood Press Cardiovasc Prev
DOI: 10.1007/s40292-022-00515-8
sha: abeed5811519a6ec983ac20bd7d28d5ae308761c
doc_id: 855447
cord_uid: xm3eos7c

nan

patients with COVID-19 was significantly associated with lower odds of mortality (odds ratio = 0.65, 95% confidence interval 0.49-0.86) and lower odds of severe disease (odds ratio = 0.61, 95% confidence interval 0.44-0.84) compared with non-use of CCBs. While the calcium channels blocking effects of CCBs in the lungs and vascular system may mitigate the inflammatory effects of COVID-19, it seems that such an effect is inadequate to provide mortality benefits [2] . The same occurs with the use of RAS inhibitors in patients with COVID-19, in which the observational evidence [6] reported positive effects, but the randomized trials [7] reported neutral effects.

Therefore, instead of administering CCBs alone or RAS inhibitors alone to patients with COVID-19, it might be better to combine the two agents. The combination of CCBs and RAS inhibitors has synergistic effects that improve endothelial function, reduce oxidative stress, and suppress inflammatory responses, especially in the arterial vasculature [8] . Several clinical trials in patients with hypertension have demonstrated the efficacy of such combination therapy; most notably the landmark ACCOMPLISH trial [9] , which randomized patients to combination therapy with benazepril plus either amlodipine or hydrochlorothiazide and reported that the primary endpoint, which was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death or coronary revascularization, achieved significantly less often in the benazepril-amlodipine group (hazard ratio: 0.80; 95% confidence interval 0.72-0.90).

Therefore, we believe that instead of investigating the use of CCBs alone (or RAS inhibitors alone) to patients with COVID-19, the combination therapy with CCBs and RAS inhibitors which can potentially counteract the endothelial activation and dysfunction involved in COVID-19 pathogenesis should be further investigated, preferably in randomized trials, to undertand its clinical implications in patients with COVID-19.

Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19

Association of Renin-Angiotensin-Aldosterone System inhibition with Covid-19 hospitalization and all-cause mortality in the UK Biobank

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial

Calcium channel blockers and the risk of all-cause mortality and severe illness in patients with COVID-19

Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis

Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis

Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials

Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients